J Edeline1, J-F Blanc2, B Campillo-Gimenez1, Y-T Ma3, J King4, O Faluyi5, J Mathurin2, S Ghazi3, D H Palmer5, T Meyer6. 1. Oncology, Centre Eugène Marquis, Rennes, France. 2. Hepatology, CHU Hôpital Saint André, Bordeaux, France. 3. Oncology, University Hospitals Birmingham NHS Foundation Trust, United Kingdom. 4. Oncology, Royal Free Hospital, London, United Kingdom. 5. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, United Kingdom; The Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom. 6. Oncology, Royal Free Hospital, London, United Kingdom; UCL Cancer Institute, University College London, London, United Kingdom. Electronic address: t.meyer@ucl.ac.uk.
Abstract
BACKGROUND: No prognostic classification is currently used for patients treated with systemic therapies for Hepatocellular Carcinoma (HCC). METHODS: We retrospectively analysed data from patients treated with sorafenib for HCC from five centres in France and in the United Kingdom (UK). The training set comprised data from two centres and the validation set from three. Variables independently associated with Overall Survival (OS) in the training set were used to build the SAP (Sorafenib Advanced HCC Prognosis) score. The score was tested in the validation set, then compared with other prognostication systems. RESULTS: The training set and validation set included 370 and 468 patients respectively. In the training set, variables independently associated with OS in multivariable analysis were: performance status (PS) >0, alpha-fetoprotein (AFP) >400 ng/ml, tumour size >7 cm, bilirubin >17 μmol/l and albumin <36 g/l. The SAP score was built giving one point to each abnormal variable, and three classes were constructed. The SAP score was significantly associated with OS in the training set, with median OS of 14.9 months for SAP A, 7.2 months for SAP B and 2.5 months for SAP C (P < 0.001). In the validation set, the SAP score was significantly associated with OS, and showed greater discriminative abilities than Barcelona Clinic Liver Cancer (BCLC) and albumin-bilirubin (ALBI) scores. However, the hepatoma arterial embolisation prognostic (HAP) score showed greater discriminative abilities than the SAP score. CONCLUSION: In European patients treated with sorafenib, the HAP was the most discriminant prognostic score and may facilitate stratification in trials and inform clinical decision making.
BACKGROUND: No prognostic classification is currently used for patients treated with systemic therapies for Hepatocellular Carcinoma (HCC). METHODS: We retrospectively analysed data from patients treated with sorafenib for HCC from five centres in France and in the United Kingdom (UK). The training set comprised data from two centres and the validation set from three. Variables independently associated with Overall Survival (OS) in the training set were used to build the SAP (Sorafenib Advanced HCC Prognosis) score. The score was tested in the validation set, then compared with other prognostication systems. RESULTS: The training set and validation set included 370 and 468 patients respectively. In the training set, variables independently associated with OS in multivariable analysis were: performance status (PS) >0, alpha-fetoprotein (AFP) >400 ng/ml, tumour size >7 cm, bilirubin >17 μmol/l and albumin <36 g/l. The SAP score was built giving one point to each abnormal variable, and three classes were constructed. The SAP score was significantly associated with OS in the training set, with median OS of 14.9 months for SAP A, 7.2 months for SAP B and 2.5 months for SAP C (P < 0.001). In the validation set, the SAP score was significantly associated with OS, and showed greater discriminative abilities than Barcelona Clinic Liver Cancer (BCLC) and albumin-bilirubin (ALBI) scores. However, the hepatoma arterial embolisation prognostic (HAP) score showed greater discriminative abilities than the SAP score. CONCLUSION: In European patients treated with sorafenib, the HAP was the most discriminant prognostic score and may facilitate stratification in trials and inform clinical decision making.
Authors: James S Leathers; Domingo Balderramo; Jhon Prieto; Fernando Diehl; Esteban Gonzalez-Ballerga; Melina R Ferreiro; Enrique Carrera; Fernando Barreyro; Javier Diaz-Ferrer; Dupinder Singh; Angelo Z Mattos; Flair Carrilho; Jose D Debes Journal: Hepat Mon Date: 2018-10-21 Impact factor: 0.660
Authors: Tim A Labeur; Sarah Berhane; Julien Edeline; Jean-Frederic Blanc; Dominik Bettinger; Tim Meyer; Jeroen L A Van Vugt; David W G Ten Cate; Robert A De Man; Ferry A L M Eskens; Alessandro Cucchetti; Laura J Bonnett; Otto M Van Delden; Heinz-Josef Klümpen; R Bart Takkenberg; Philip J Johnson Journal: Liver Int Date: 2019-11-18 Impact factor: 5.828
Authors: Giovanni Marasco; Francesco Poggioli; Antonio Colecchia; Giuseppe Cabibbo; Filippo Pelizzaro; Edoardo Giovanni Giannini; Sara Marinelli; Gian Ludovico Rapaccini; Eugenio Caturelli; Mariella Di Marco; Elisabetta Biasini; Fabio Marra; Filomena Morisco; Francesco Giuseppe Foschi; Marco Zoli; Antonio Gasbarrini; Gianluca Svegliati Baroni; Alberto Masotto; Rodolfo Sacco; Giovanni Raimondo; Francesco Azzaroli; Andrea Mega; Gianpaolo Vidili; Maurizia Rossana Brunetto; Gerardo Nardone; Luigina Vanessa Alemanni; Elton Dajti; Federico Ravaioli; Davide Festi; Franco Trevisani; On Behalf Of The Italian Liver Cancer Ita Li Ca Group Journal: Cancers (Basel) Date: 2021-05-29 Impact factor: 6.639